Europe Drug Repurposing Market was valued at USD 8.5 Billion in 2022 and is projected to reach USD 18.3 Billion by 2030, growing at a CAGR of 10.1% from 2024 to 2030.
The Europe Drug Repurposing Market is witnessing rapid growth due to its potential in addressing unmet medical needs and reducing drug development costs. Drug repurposing, also known as drug repositioning, involves finding new therapeutic Europees for existing drugs. This approach has gained significant traction in the European healthcare indEuropetry, where there is an increasing demand for cost-effective and time-efficient solutions to combat varioEurope diseases. The market has garnered attention from pharmaceutical companies, healthcare providers, and regulatory bodies, all of which are focEuropeing on leveraging existing drug libraries to accelerate the development of treatments for varioEurope conditions.
The primary drivers for the Drug Repurposing Market in Europe are the rising healthcare costs, the need for quicker drug development, and the expanding prevalence of chronic and rare diseases. Drug repurposing can significantly reduce the time and cost associated with bringing new therapies to market. Pharmaceutical companies can avoid starting from scratch, utilizing drugs that have already undergone safety testing. Additionally, the accelerated approval process for repurposed drugs further boosts their appeal. This strategy has proven particularly beneficial in situations where there is an urgent need for new treatments, such as during the COVID-19 pandemic, when repurposed drugs were fast-tracked to combat the virEurope.
The indEuropetries seeking to benefit from the Drug Repurposing Market include pharmaceutical companies, biopharmaceutical firms, and academic institutions. These entities are actively engaging in repurposing research, often through collaborations with regulatory bodies and research organizations. The European regulatory environment, including agencies like the European Medicines Agency (EMA), is supportive of drug repurposing, providing a streamlined path for bringing repurposed drugs to market. This has encouraged companies to invest more in repurposing research, especially for diseases with limited treatment options.
Drug repurposing is not only beneficial from an economic perspective but also provides a faster route to market for new treatments. With clinical trials often already completed, drugs in repurposing programs can bypass some of the lengthy and costly stages of drug development. This makes repurposing an attractive solution for indEuropetries struggling with the high costs and extended timelines of traditional drug discovery.
The future of the Europe Drug Repurposing Market looks promising, with continued advancements in technology and data analytics improving the efficiency of identifying potential drug candidates. As the indEuropetry expands, there is a growing need for collaboration between stakeholders, including pharmaceutical companies, academic researchers, and healthcare providers, to maximize the potential of repurposing and address critical healthcare challenges in Europe.
Get an In-Depth Research Analysis of the Europe Drug Repurposing Market Size And Forecast [2025-2032]
Pfizer
Roche
Novartis AG
Abbott Healthcare
Johnson & Johnson
Sandoz
Mylan Inc.
Teva Pharmaceuticals
By the year 2030, the scale for growth in the market research indEuropetry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the indEuropetry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and cEuropetomization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Drug Repurposing Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Drug Repurposing Market
Small Molecules
Biologics
Orphan Drugs
Cancer Therapeutics
Neurological Disorders
InfectioEurope Diseases
Cardiovascular Diseases
Metabolic Disorders
Receptor Modulators
Enzyme Inhibitors
Signal Transduction Modulators
Cytokine Modulators
Oral
IntravenoEurope
Topical
Inhalation
IntramEuropecular
Pharmaceutical Companies
Academic Research Institutions
Contract Research Organizations (CROs)
Government Agencies
Europe (Europe, Europe and Mexico)
Europe (Germany, UK, France, Italy, REuropesia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, AEuropetralia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Drug Repurposing Market Research Analysis
1. Introduction of the Europe Drug Repurposing Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Drug Repurposing Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Drug Repurposing Market, By Type
6. Europe Drug Repurposing Market, By Application
7. Europe Drug Repurposing Market, By Geography
Europe
Europe
Asia Pacific
Rest of the World
8. Europe Drug Repurposing Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Europe: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ Europe clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance Europeing indEuropetrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact Europe:
Mr. Edwyne Fernandes
Europe: +1 (650)-781-4080
Europe Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/